S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
How A.I. Could Make Most 21st Century Diseases EXTINCT (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Laser breakthrough could send stock soaring 2,467% (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
With oil prices slumping, OPEC+ producers weigh more production cuts
Laser breakthrough could send stock soaring 2,467% (Ad)
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
Twitter executive responsible for content safety resigns after Elon Musk criticism
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
How A.I. Could Make Most 21st Century Diseases EXTINCT (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Laser breakthrough could send stock soaring 2,467% (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
With oil prices slumping, OPEC+ producers weigh more production cuts
Laser breakthrough could send stock soaring 2,467% (Ad)
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
Twitter executive responsible for content safety resigns after Elon Musk criticism
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
How A.I. Could Make Most 21st Century Diseases EXTINCT (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Laser breakthrough could send stock soaring 2,467% (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
With oil prices slumping, OPEC+ producers weigh more production cuts
Laser breakthrough could send stock soaring 2,467% (Ad)
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
Twitter executive responsible for content safety resigns after Elon Musk criticism
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
How A.I. Could Make Most 21st Century Diseases EXTINCT (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Laser breakthrough could send stock soaring 2,467% (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
With oil prices slumping, OPEC+ producers weigh more production cuts
Laser breakthrough could send stock soaring 2,467% (Ad)
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
Twitter executive responsible for content safety resigns after Elon Musk criticism

Sangamo Therapeutics (SGMO) Stock Forecast, Price & News

$1.15
+0.04 (+3.60%)
(As of 06/2/2023 ET)
Compare
Today's Range
$1.10
$1.16
50-Day Range
$1.11
$1.76
52-Week Range
$1.07
$6.42
Volume
1.99 million shs
Average Volume
2.41 million shs
Market Capitalization
$197.60 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.91

Sangamo Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.60 Rating Score
Upside/​Downside
675.2% Upside
$8.91 Price Target
Short Interest
Healthy
10.25% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.77) to ($1.16) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.02 out of 5 stars

Medical Sector

506th out of 983 stocks

Biological Products, Except Diagnostic Industry

85th out of 164 stocks


SGMO stock logo

About Sangamo Therapeutics (NASDAQ:SGMO) Stock

Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. It focuses on three therapeutic areas: inherited metabolic diseases, central nervous system, and diseases and immunology, which comprises inflammatory and autoimmune diseases. It also offers complementary technology platforms such as gene therapy, ex vivo cell therapy, in vivo genome editing, and in vivo genome regulation. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Brisbane, CA.

Receive SGMO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sangamo Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SGMO Stock News Headlines

Our #1 Laser Stock for May
The Pentagon calls laser weapons "the future." This small cap just won a $1.65 billion contract to make them. See why this stock could soar 2,476% >>>
Small A.I. Firm Wins $2 Billion in Contracts for Breakthrough "Living Software"
Denver firm proves its possible to use AI to save the lives of soldiers in combat. England, Germany, Japan and Australia have all signed contracts within the past 18 months. Get the name of the stock here >>>
The Latest Analyst Ratings for Sangamo Therapeutics
Sangamo Therapeutics (SGMO) to Release Earnings on Wednesday
See More Headlines

SGMO Price History

SGMO Company Calendar

Last Earnings
2/22/2023
Today
6/03/2023
Next Earnings (Estimated)
8/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:SGMO
CUSIP
80067710
Employees
431
Year Founded
1995

Price Target and Rating

Average Stock Price Forecast
$8.91
High Stock Price Forecast
$16.00
Low Stock Price Forecast
$1.50
Forecasted Upside/Downside
+675.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.60
Research Coverage
5 Analysts

Profitability

Net Income
$-192,280,000.00
Pretax Margin
-52.53%

Debt

Sales & Book Value

Annual Sales
$111.30 million
Book Value
$1.95 per share

Miscellaneous

Free Float
166,671,000
Market Cap
$197.60 million
Optionable
Optionable
Beta
1.07

Social Links


Key Executives

  • Alexander D. Macrae
    President, Chief Executive Officer & Director
  • Mark D. McClung
    Chief Operating Officer & Executive Vice President
  • Prathyusha Durabaibu
    Chief Financial & Accounting Officer, Senior VP
  • R. Andrew Ramelmeier
    Executive Vice President-Technical Operations
  • Jason D. Fontenot
    Chief Scientific Officer & Senior Vice President













SGMO Stock - Frequently Asked Questions

Should I buy or sell Sangamo Therapeutics stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sangamo Therapeutics in the last twelve months. There are currently 1 sell rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SGMO shares.
View SGMO analyst ratings
or view top-rated stocks.

What is Sangamo Therapeutics' stock price forecast for 2023?

5 brokerages have issued 12-month price targets for Sangamo Therapeutics' shares. Their SGMO share price forecasts range from $1.50 to $16.00. On average, they expect the company's share price to reach $8.91 in the next year. This suggests a possible upside of 675.2% from the stock's current price.
View analysts price targets for SGMO
or view top-rated stocks among Wall Street analysts.

How have SGMO shares performed in 2023?

Sangamo Therapeutics' stock was trading at $3.14 at the start of the year. Since then, SGMO shares have decreased by 63.4% and is now trading at $1.15.
View the best growth stocks for 2023 here
.

When is Sangamo Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our SGMO earnings forecast
.

How were Sangamo Therapeutics' earnings last quarter?

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) released its quarterly earnings data on Wednesday, February, 22nd. The biopharmaceutical company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.36) by $0.04. The biopharmaceutical company earned $27.23 million during the quarter, compared to analyst estimates of $26.86 million. Sangamo Therapeutics had a negative net margin of 52.76% and a negative trailing twelve-month return on equity of 40.44%. The firm's revenue was down 2.7% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.26) EPS.

What guidance has Sangamo Therapeutics issued on next quarter's earnings?

Sangamo Therapeutics issued an update on its first quarter 2023 earnings guidance on Thursday, April, 27th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $158.00 million-$158.00 million.

What is Sandy Macrae, M.B., Ch.B., Ph.D.'s approval rating as Sangamo Therapeutics' CEO?

10 employees have rated Sangamo Therapeutics Chief Executive Officer Sandy Macrae, M.B., Ch.B., Ph.D. on Glassdoor.com. Sandy Macrae, M.B., Ch.B., Ph.D. has an approval rating of 89% among the company's employees.

What other stocks do shareholders of Sangamo Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sangamo Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), CRISPR Therapeutics (CRSP), Novavax (NVAX), Gilead Sciences (GILD), Brainstorm Cell Therapeutics (BCLI), Editas Medicine (EDIT), Netflix (NFLX) and Intel (INTC).

What is Sangamo Therapeutics' stock symbol?

Sangamo Therapeutics trades on the NASDAQ under the ticker symbol "SGMO."

Who are Sangamo Therapeutics' major shareholders?

Sangamo Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (9.22%), Wasatch Advisors LP (7.94%), State Street Corp (5.21%), Credit Suisse AG (2.23%), Dimensional Fund Advisors LP (1.92%) and Renaissance Technologies LLC (1.88%). Insiders that own company stock include Biogen Inc, Gary Loeb, John Markels, Rolf Andrew Ramelmeier and Saira Ramasastry.
View institutional ownership trends
.

How do I buy shares of Sangamo Therapeutics?

Shares of SGMO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sangamo Therapeutics' stock price today?

One share of SGMO stock can currently be purchased for approximately $1.15.

How much money does Sangamo Therapeutics make?

Sangamo Therapeutics (NASDAQ:SGMO) has a market capitalization of $197.60 million and generates $111.30 million in revenue each year. The biopharmaceutical company earns $-192,280,000.00 in net income (profit) each year or ($0.83) on an earnings per share basis.

How many employees does Sangamo Therapeutics have?

The company employs 431 workers across the globe.

How can I contact Sangamo Therapeutics?

Sangamo Therapeutics' mailing address is 7000 MARINA BLVD, BRISBANE CA, 94005. The official website for the company is www.sangamo.com. The biopharmaceutical company can be reached via phone at (510) 970-6000, via email at investor.relations@sangamo.com, or via fax at 510-236-8951.

This page (NASDAQ:SGMO) was last updated on 6/4/2023 by MarketBeat.com Staff

My Account -